Ekso Bionics(TM) Named One of "5 Startups Poised to Change MedTech Forever"
February 13 2014 - 05:00PM
Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton
company, today announced that it was named one of five startups
poised to change MedTech forever by Medical Device & Diagnostic
Industry Magazine. MD+DI 's editorial quality and reliability has
won it an unparalleled degree of trust from the industry. For more
than 30 years, MD+DI has served the industry as the leading
source of in-depth news and information; many of their articles
have become standards of reference for the medical device industry.
"We are honored to be recognized by MD+DI," said Nathan Harding,
Company CEO. "It validates our drive to define the industry for
exoskeletons, and, as Arundhati Parmar, MD + DI's Editor and
article author states we have taken great strides."
Ekso Bionics designs, develops, and commercializes exoskeletons,
or wearable robots, which have a variety of applications in the
medical, military, industrial, and consumer markets. Exoskeletons
are ready-to-wear, battery-powered robots that are strapped over
the user's clothing, enabling individuals to achieve mobility,
strength, and endurance not otherwise possible.
Ekso Bionics' lead product, EksoTM, is a wearable bionics suit
that enables individuals with any amount of lower extremity
weakness to stand up and walk over ground. Ekso is forging a new
frontier in rehabilitation for people living with the consequences
of stroke, spinal cord injury and other neurological conditions
affecting gait.
About Ekso Bionics
Since 2005, Ekso Bionics (http://www.eksobionics.com) has been
pioneering the field of robotic exoskeletons, or wearable robots,
to augment human strength, endurance and mobility. The company's
first commercially available product called Ekso has helped
thousands of people living with paralysis take millions of steps
not otherwise possible. By designing and creating some of the most
forward-thinking and innovative solutions for people looking to
augment human capabilities, Ekso Bionics is helping people rethink
current physical limitations and achieve the remarkable.
Facebook: www.facebook.com/eksobionics Twitter: @eksobionics
YouTube: http://www.youtube.com/user/EksoBionics/
Media Contact: Heidi Darling, Marketing Manager
Phone: 415.302.4777 hdarling@eksobionics.com
Investor Contact: Lauren Glaser, Vice President
Phone: 646.378.2972 lglaser@troutgroup.com
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Forward-looking statements may include, without
limitation, statements regarding (i) the plans and objectives of
management for future operations, including plans or objectives
relating to the design, development and commercialization of human
exoskeletons, (ii) a projection of income (including income/loss),
earnings (including earnings/loss) per share, capital expenditures,
dividends, capital structure or other financial items, (iii) the
Company's future financial performance and (iv) the assumptions
underlying or relating to any statement described in points (i),
(ii) or (iii) above. Such forward-looking statements are not
meant to predict or guarantee actual results, performance, events
or circumstances and may not be realized because they are based
upon the Company's current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or
contribute to the inaccuracy of the forward-looking statements or
cause actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time and
resources associated with the development of our products and
related insufficient cash flows and resulting illiquidity, the
Company's inability to expand the Company's business, significant
government regulation of medical devices and the healthcare
industry, lack of product diversification, volatility in the price
of the Company's raw materials, existing or increased competition,
results of arbitration and litigation, stock volatility and
illiquidity, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC, including, the Company's Current Report on Form 8-K
filed on January 23, 2014. The Company does not undertake to
update these forward-looking statements.
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2023 to Mar 2024